A Phase 3 Clinical Testing of 0.5% ADX-102 for Allergic Conjunctivitis
Phase of Trial: Phase III
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Reproxalap (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- 09 Nov 2017 According to an Aldeyra Therapeutics media release, this trial is expected to begin in the first half of 2018. Results are expected to be announced in the second half of 2018.
- 21 Jun 2017 New trial record
- 14 Jun 2017 Accordin to an Aldeyra Therapeutics media release, based on the data from another trial (see profile 277242) the company plans to initiate this trial following discussion with the regulatory authorities in the second half of 2017.